
LucidHealth names David Grau as CEO
Grau will become CEO on May 1, with Steve Corbeil moving to executive chairman of the board as part of a planned succession.
Section
M&A, vendor news, reimbursement, and the economics of imaging.

Grau will become CEO on May 1, with Steve Corbeil moving to executive chairman of the board as part of a planned succession.

The funding will support product development and international expansion of ScreenPoint Medical’s Transpara breast AI solutions.

Microbot began full market release of its FDA-cleared, single-use endovascular robotic system at the Society of Interventional Radiology meeting.

The approval covers Vueway injection, a macrocyclic gadolinium-based contrast agent for contrast-enhanced MRI in adults and children 2 years and older.

Digital X-Ray Imaging will market, install, and support the FDA-cleared multisource digital tomosynthesis system across Arkansas.

The companies will co-develop radiopharmaceutical therapies and radiodiagnostics across multiple solid tumor targets.

The 6F neurovascular access catheter is the company’s third FDA-cleared catheter and is designed for MMA embolization and radial access procedures.